Compare ALEMBIC LTD with Divis Laboratories - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC LTD vs DIVIS LABORATORIES - Comparison Results

ALEMBIC LTD     Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC LTD DIVIS LABORATORIES ALEMBIC LTD/
DIVIS LABORATORIES
 
P/E (TTM) x 66.7 32.7 203.7% View Chart
P/BV x 2.4 7.4 32.1% View Chart
Dividend Yield % 0.4 0.6 70.8%  

Financials

 ALEMBIC LTD   DIVIS LABORATORIES
EQUITY SHARE DATA
    ALEMBIC LTD
Mar-18
DIVIS LABORATORIES
Mar-18
ALEMBIC LTD/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs721,142 6.3%   
Low Rs34533 6.4%   
Sales per share (Unadj.) Rs4.7146.6 3.2%  
Earnings per share (Unadj.) Rs6.133.0 18.5%  
Cash flow per share (Unadj.) Rs6.238.4 16.3%  
Dividends per share (Unadj.) Rs0.2010.00 2.0%  
Dividend yield (eoy) %0.41.2 31.6%  
Book value per share (Unadj.) Rs40.7222.8 18.2%  
Shares outstanding (eoy) m267.03265.47 100.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x11.35.7 197.2%   
Avg P/E ratio x8.725.3 34.2%  
P/CF ratio (eoy) x8.521.8 38.9%  
Price / Book Value ratio x1.33.8 34.7%  
Dividend payout %3.330.3 10.8%   
Avg Mkt Cap Rs m14,139222,318 6.4%   
No. of employees `000NA10.8 0.0%   
Total wages/salary Rs m2074,561 4.5%   
Avg. sales/employee Rs ThNM3,616.0-  
Avg. wages/employee Rs ThNM423.8-  
Avg. net profit/employee Rs ThNM814.9-  
INCOME DATA
Net Sales Rs m1,25538,915 3.2%  
Other income Rs m3701,134 32.6%   
Total revenues Rs m1,62540,049 4.1%   
Gross profit Rs m11112,617 0.9%  
Depreciation Rs m381,425 2.7%   
Interest Rs m213 12.8%   
Profit before tax Rs m44212,313 3.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m1,2120-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m243,543 0.7%   
Profit after tax Rs m1,6308,770 18.6%  
Gross profit margin %8.932.4 27.3%  
Effective tax rate %5.428.8 18.8%   
Net profit margin %129.822.5 576.2%  
BALANCE SHEET DATA
Current assets Rs m1,86745,351 4.1%   
Current liabilities Rs m5916,507 9.1%   
Net working cap to sales %101.699.8 101.8%  
Current ratio x3.27.0 45.3%  
Inventory Days Days94127 74.4%  
Debtors Days Days7495 77.3%  
Net fixed assets Rs m1,79121,160 8.5%   
Share capital Rs m534531 100.6%   
"Free" reserves Rs m10,32458,625 17.6%   
Net worth Rs m10,85859,156 18.4%   
Long term debt Rs m410-   
Total assets Rs m11,59167,832 17.1%  
Interest coverage x260.9926.8 28.1%   
Debt to equity ratio x00-  
Sales to assets ratio x0.10.6 18.9%   
Return on assets %14.112.9 108.7%  
Return on equity %15.014.8 101.3%  
Return on capital %15.220.8 72.9%  
Exports to sales %1.50-   
Imports to sales %21.021.8 96.2%   
Exports (fob) Rs m19NA-   
Imports (cif) Rs m2638,485 3.1%   
Fx inflow Rs m1932,359 0.1%   
Fx outflow Rs m2649,042 2.9%   
Net fx Rs m-24423,317 -1.0%   
CASH FLOW
From Operations Rs m2367,759 3.0%  
From Investments Rs m-224-4,783 4.7%  
From Financial Activity Rs m-27-3,142 0.8%  
Net Cashflow Rs m-15-166 8.9%  

Share Holding

Indian Promoters % 64.0 52.0 123.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.2 11.8 1.7%  
FIIs % 9.7 19.0 51.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.1 17.2 151.7%  
Shareholders   54,701 31,796 172.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC LTD With:   SHASUN PHARMA  WYETH LTD  GSK PHARMA  FULFORD INDIA  DR. REDDYS LAB  

Compare ALEMBIC LTD With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 262 Points Lower; Oil & Gas and Banking Stocks Witness Selling(Closing)

Indian share markets witnessed negative trading activity throughout the day and ended lower. At the closing bell, the BSE Sensex stood lower by 262 points (down 0.7%).

Related Views on News

ALEMBIC LTD Announces Quarterly Results (1QFY20); Net Profit Down 70.9% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, ALEMBIC LTD has posted a net profit of Rs 20 m (down 70.9% YoY). Sales on the other hand came in at Rs 260 m (down 41.5% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (1QFY20); Net Profit Up 0.4% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 0.4% YoY). Sales on the other hand came in at Rs 11 bn (up 14.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (4QFY19); Net Profit Up 10.6% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 10.6% YoY). Sales on the other hand came in at Rs 13 bn (up 15.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

ALEMBIC LTD Announces Quarterly Results (4QFY19); Net Profit Down 14.6% (Quarterly Result Update)

May 17, 2019 | Updated on May 17, 2019

For the quarter ended March 2019, ALEMBIC LTD has posted a net profit of Rs 40 m (down 14.6% YoY). Sales on the other hand came in at Rs 253 m (down 23.8% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (3QFY19); Net Profit Up 68.9% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 68.9% YoY). Sales on the other hand came in at Rs 13 bn (up 29.4% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Insider Buying Alert: Promoters Increase Stake in 8 High-Quality Smallcaps(Profit Hunter)

Sep 3, 2019

Insiders have increased their stakes in eight Hidden Treasure recommendations. Should you follow them?

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC LTD SHARE PRICE


Sep 16, 2019 (Close)

TRACK ALEMBIC LTD

  • Track your investment in ALEMBIC LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ALEMBIC LTD - ALEMBIC PHARMA COMPARISON

COMPARE ALEMBIC LTD WITH

MARKET STATS